Results 11 to 20 of about 528,622 (127)

Efficacy of CytoSorb®: a systematic review and meta-analysis [PDF]

Critical Care, 2023
Introduction Cytokine adsorption using the CytoSorb® adsorber has been proposed in various clinical settings including sepsis, ARDS, hyperinflammatory syndromes, cardiac surgery or recovery after cardiac arrest.
Sören Becker, Hannah Lang, Clara Vollmer Barbosa, Zhejia Tian, Anette Melk, Bernhard M. W. Schmidt   +5 more
doaj   +3 more sources

Hematological parameter dynamics in critically ill patients treated with oXiris®-based CRRT and CytoSorb® hemoadsorption: a prospective single-center study [PDF]

BMC Nephrology
Background Hemoadsorption is increasingly used as adjunctive extracorporeal support in sepsis and septic shock. Comparative data on device-specific hematologic effects remain limited. CytoSorb® and oXiris® are among the most widely applied hemoadsorption
Nikolina Špirić, Katarina Vučićević, Jesús Villar, Tijana Kovačević, Saša Dragić, Biljana Zlojuto, Danica Momčičević, Milka Jandrić, Grozdana Klječanin, Pedja Kovačević   +9 more
doaj   +3 more sources

Systemic Mastocytosis Successfully Managed using Cytosorb® During Cardiopulmonary Bypass for Aortic Valve Replacement [PDF]

Annals of Cardiac Anaesthesia
We describe the case of a 72-year-old male with a history of systemic mastocytosis scheduled for on-pump aortic valve replacement for severe aortic insufficiency.
Adrien Gross, Sébastien Colombier, Lionel Arlettaz, Dominique Delay   +3 more
doaj   +3 more sources

Potential Clinical Use of CytoSorb^® for Ticagrelor and Rivaroxaban Elimination Prior to Emergency Orthopedic Surgery in Trauma Patients [PDF]

Life
Background: Major orthopedic trauma in patients receiving anticoagulants such as ticagrelor or rivaroxaban poses a significant perioperative challenge, particularly in emergency contexts where bleeding risks are heightened and specific reversal agents ...
Gabriele Melegari, Fabio Gazzotti, Federica Arturi, Elisabetta Bertellini, Andrea Tognù, Domenico Pietro Santonastaso, Matteo Villani, Francesca Coppi, Fabrizio Fattorini, Fabio Catani, Alberto Barbieri   +10 more
doaj   +3 more sources

CytoSorb® Hemoadsorption as a Promising Tool to Handle COVID-19-Induced Cytokine Storm [PDF]

Case Reports in Critical Care, 2021
Accumulating evidence suggests that a patient subgroup with severe COVID-19 develops a cytokine release syndrome leading to capillary leakage and organ injury.
Alice-Christin Acevedo, Michael Zoller, Christina Scharf, Uwe Liebchen, Michael Irlbeck, Ines Schroeder   +5 more
doaj   +3 more sources

Does the cytokine adsorber CytoSorb® reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study [PDF]

Annals of Intensive Care, 2022
Background Hemadsorption of cytokines is used in critically ill patients with sepsis or septic shock. Concerns have been raised that the cytokine adsorber CytoSorb® unintentionally adsorbs vancomycin.
Christina Scharf, Ferdinand Weinelt, Ines Schroeder, Michael Paal, Michael Weigand, Michael Zoller, Michael Irlbeck, Charlotte Kloft, Josef Briegel, Uwe Liebchen   +9 more
doaj   +2 more sources

Impact of CytoSorb® on interleukin-6 in cardiac surgery [PDF]

Frontiers in Cardiovascular Medicine, 2023
ObjectiveCardiac surgery is known to activate a cascade of inflammatory mediators leading to a systemic inflammatory response. Hemadsorption (HA) devices such as CytoSorb® have been postulated to mitigate an overshooting immune response, which is ...
Daniela Geisler, Daniela Geisler, Noemi Arleth, Johannes Grabenwöger, Zsuzsanna Arnold, Zsuzsanna Arnold, Thomas Aschacher, Thomas Aschacher, Bernhard Winkler, Bernhard Winkler, Bernhard Winkler, Markus Mach, Martin Grabenwöger, Martin Grabenwöger, Martin Grabenwöger   +14 more
doaj   +2 more sources

Antibiotics and Other Drugs Removal by the CytoSorb^® Haemoadsorber: A Systematic Review of Available Evidence [PDF]

Antibiotics
Background/Objectives: Haemoadsorption has recently emerged as an extracorporeal treatment option for sepsis, septic shock, intoxications, and cardiac surgery to modulate dysregulated inflammatory responses or remove a wide range of circulating molecules.
Sara Kenda, Jakob Gubenšek, Tomaž Vovk
doaj   +2 more sources

Early impact of CytoSorb® adsorber on proinflammatory cytokine plasmatic levels in a porcine model of refractory cardiogenic shock supported with VA-ECMO [PDF]

BMC Cardiovascular Disorders
Background Cardiogenic shock (CS) is a pejorative situation which often requires a circulatory support with VA-ECMO. However, VA-ECMO is known to trigger an inflammatory cascade with expression of proinflammatory cytokines Interleukin-6 (IL-6) and ...
Juliette Piccoli, Tristan Ehrlich, Francesco Ferraro, Aude Falanga, Frédérique Groubatch-Joineau, Vanessa Marie, Fabrice Vanhuyse, Nguyen Tran, Daniel Grandmougin, Juan-Pablo Maureira   +9 more
doaj   +2 more sources

CytoSorb® therapy: a new approach to treat critically ill patients with COVID-19 – a retrospective study [PDF]

International Journal of Medical Device and Adjuvant Treatments, 2023
Objective: The Coronavirus 2019 (COVID-19) pandemic has resulted in significant mortality and morbidity. Patients with severe COVID-19 infection experience cytokine storm that makes the treatment approach more challenging.
K. Patil, M. Priyadarsini
doaj   +3 more sources